Table 3 Population secondary pharmacokinetic parameters.

From: A multicentre phase 1b/2 study of tivozanib in patients with advanced inoperable hepatocellular carcinoma

Day

Dose (mg)

AUC0–4 (h*ng/mL)

AUC0–24 (h*ng/mL)

Cmax (ng/mL)

tmax (h)

Mean

Standard deviation

Mean

Standard deviation

Mean

Standard deviation

Median

Range

NCA and observation

         

 1

1

14.22

7.87

NE

NE

6.54

3.82

4.067

2.05–7.67

 15

1

184.33

98.14

NE

NE

58.67

36.84

2.05

2.00–4.12

Model prediction

         

 1

1

14.28

7.66

175.98

74.29

8.75

3.27

13.33

9.63–23.97

 15

1

190.06

90.79

1104.89

589.09

50.67

23.35

7.00

5.97–17.93

  1. NCA non-compartmental analysis, AUC0–4 and AUC0–24 area under the concentration–time curve from 0 to 4 and 0 to 24 h, respectively, NE not estimated.
Back to article page